. "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . . . "\u056F\u056C\u056B\u0576\u056B\u056F\u0561\u056F\u0561\u0576 \u0583\u0578\u0580\u0571\u0561\u0580\u056F\u0578\u0582\u0574"@hy . "85"^^ . . . "Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease"@en . . . . "Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease"@en . . . "REVERSE-SD"@en . "A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease"@en . "Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease"@en . . . . "ensayu cl\u00EDnicu"@ast . . . . "klinisch onderzoek"@nl . . "55"^^ . . "2017-12-29T00:00:00Z"^^ . . "NCT03402659" . . . "clinical trial"@en . "2019-06-30T00:00:00Z"^^ . . "161"^^ . .